Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“In newly diagnosed Multiple Myeloma, the frontline conversation is no longer just about response.
It’s about depth of response.
And increasingly, MRD negativity is becoming the language of modern myeloma therapy.
The phase 3 EMN24 IsKia trial asked a critical question:
Does adding Isatuximab to KRd push responses deeper in transplant-eligible patients?
The answer appears to be yes.
Isa-KRd achieved:
- Higher MRD negativity after induction
- Higher MRD negativity after consolidation
- More sustained MRD-negative remissions
And importantly: The advantage persisted even at ultra-deep sensitivity thresholds (10⁻⁶)
The story here is about trajectory.
These deeper responses emerged: Earlier, More frequently, More durably, without major increases in toxicity.
Bottom line: In myeloma, the field is moving beyond ‘did the patient respond?’
Toward: How deep, How early, How durable
And quadruplet therapy continues pushing that bar higher.”
Title: Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
Authors: Francesca Gay, Wilfried Roeloffzen, Meletios Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez Otero, Roman Hájek, Elisabetta Antonioli, Mark van Duin, Mattia D’Agostino, Joaquín Martínez-López, Elena van Leeuwen-Segarceanu, Elena Zamagni, Niels van de Donk, Katja Weisel, Luděk Pour, Jakub Radocha, Angelo Belotti, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Pieter Sonneveld, Mario Boccadoro, Annemiek Broijl
Other articles featuring Yan Leyfman on OncoDaily.